Clinical Trial Update: Y-90 Treatment Response Using Transarterial Radioembolization [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating response to Yttrium-90 transarterial radioembolization in hepatocellular carcinoma; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Yttrium-90 radiopharmaceutical for transarterial radioembolization (Yttrium-90 microspheres)

Snippet

Sponsor: Thomas Jefferson University | Conditions: HCC, Hepatocellular Carcinoma | Phase 2 | Status: RECRUITING